Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats

Drug Metabolism and Disposition

Volumn 27, Issue 6, 1999, Pages 651-654

  Tateishi, Tomonori ^a   Watanabe, Minoru ^a   Nakura, Hironori ^a   Tanaka, Masami ^a   Kumai, Toshio ^a   Sakata, Shigeko Fujimoto ^b   Tamaki, Nanaya ^b   Ogura, Kenichiro ^c   Nishiyama, Takahito ^c   Watabe, Tadashi ^c   Kobayashi, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; LIVER INJURY; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCTS; BLOTTING, NORTHERN; BODY WEIGHT; CYTOCHROME P-450 CYP2B1; CYTOSOL; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; LIGATION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; ORGAN SIZE; OXIDOREDUCTASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

ANIMALIA;

EID: 0033054515     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Aguiar JLA, Berger MR and Frank N (1987) Locoregional application of 5-fluorouracil to the liver: Alteration of pharmacokinetics and bone marrow toxicity in rats with thioacetamide-induced cirrhosis. Toxicol Lett 36:181-188
2. Baccanari DP, Davis ST, Knick VC and Spector T (1993) 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068.
3. Butner JT, Zysset MT and Reichen J (1993) Metabolism of antipyrine in vivo in two rat models of liver cirrhosis: Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem Pharmacol 44:983-991.
4. Cao S, Rustum YM and Spector T (1994) 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510.
5. Daneshmend TK and Roberts CJC (1984) The effects of enzyme induction and enzyme inhibition of latetalol pharmacokinetics. Br J Clin Pharmacol 18:393-400.
6. Diasio RB, Beavers TL and Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51.
7. Fleming RA, Milano GA, Etienne MC, Renée N, Thyss A, Schneider M and Demard F (1992) No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer 66:668-672.
8. Fujii-Kuriyama Y, Mizukami Y, Kawajiri K, Sogawa K and Muramatsu M (1982) Primary structure of a cytochrome P-450: Coding nucleotide sequence of phenobarbital-inducible cytochrome P-450 cDNA from rat liver. Proc Natl Acad Sci USA 79:2793-2797.
9. George J, Murray M, Byth K and Farrell GC (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21:120-128.
10. Glisin V, Crkvenjakov R and Byun C (1974) Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 13:2633-2637.
11. Groszmann RJ, Vorobioff J and Riley E (1982) Splanchnic hemodynamics in portal-hypertensive rats: Measurement with γ-labeled microspheres. Am J Physiol 242:G156-G160.
12. Guenjerich FP (1992) Human cytochrome P-450 enzymes. Life Sci 50:1471-1478.
13. Kawata S, Noda S, Imai Y, Tamura S, Saitoh R, Miyoshi S, Minami Y and Tarui S (1987) Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. Gastroenterol Jpn 22:55-62.
14. Kimura M, Sakata FS, Matoba Y, Matsuda K, Kontani Y, Kaneko M and Tamaki N (1998) Cloning of rat dihydropyrimidine dehydrogenase and correlation of its mRNA increase in the rat liver with age. J Nutr Sci Vitaminol 44:537-546.
15. Kühne-Wömpner C-H, Schmoll H-J, Harstrick A and Rustum YM (1992) Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 19 (Suppl 3):105-125.
16. Kountouras J, Billing BH and Scheuer PJ (1984) Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat. Br J Exp Pathol 65:305-311.
17. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Lu Z, Zhang R and Diasio RB (1993) Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochem Pharmacol 46:945-952.
19. Malik AB, Kaplan JE and Saba TM (1976) Reference sample method for cardiac output and regional blood flow determinations in the rat. J Appl Physiol 40:472-475.
20. McLean AJ and Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42-69.
21. Mourelle M, Amezcua JL and Favari L (1987) Heterogeneity of changed on the disposition of aspirin in rats with CC14-induced chronic liver damage. Biochem Pharmacol 36:3021-3025.
22. Murray M (1992) P450 enzymes: Inhibition mechanism, genetic regulation and effects of liver disease. Clin Pharmacokinet 23:132-146.
23. Naguib FNM, el Kouni MH and Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412.
24. Nakajima IS, Hamada H, Reddy P and Kakunaga T (1985) Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the intron. Proc Natl Acad Sci USA 82:6133-6137.
25. Nowakowska-Dulawa E (1990) Circadian rhythm of 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia 17:27-35.
26. Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y and Watabe T (1998) Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 122:107-113.
27. Pinedo HM and Peters GFJ (1988) Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664.
28. Queener SF, Morris HP and Weber G (1971) Dihydrouracil dehydrogenase activity in normal, differentiating, and regenerating liver and in hepatomas. Cancer Res 31:1004-1009.
29. Tateishi T, Nakura H, Watanabe M, Tanaka M, Kumai T and Kobayashi S (1996) Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity. Clin Chim Acta 252:1-9.
30. Tateishi T, Watanabe M, Nakura H, Tanaka M, Kumai T and Kobayashi S (1998) Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats. Pharmacol Toxicol 82:89-92.
31. Tuchman M, Stoeckeler JS, Kiand DT, O'Dea RF, Ramnaraine ML and Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249.